



May 23, 2017

Retrophin to Present at the Jefferies 2017 Global Healthcare Conference

SAN DIEGO, May 23, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Jefferies 2017 Global Healthcare Conference in New York City on Tuesday, June 6, 2017 at 3:30 p.m. ET.

A live webcast of the presentation will be available at <http://ir.retrophin.com/events.cfm> and an archived replay will be accessible for up to 30 days.

About Retrophin

Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in several rare diseases is also underway. Retrophin's R&D efforts are supported by revenues from the Company's commercial products Thiola[®], Cholbam[®], and Chenodal[®].

Retrophin.com

Contact:

Chris Cline, CFA

Vice President, Investor Relations & Corporate Communications

646-564-3680

IR@retrophin.com

 [Primary Logo](#)

Source: Retrophin, Inc.

News Provided by Acquire Media